De-Escalation Strategies in HPV-Associated Oropharynx Cancer-Are we Putting the Cart Before the Horse?
- PMID: 31204653
- PMCID: PMC7194352
- DOI: 10.1016/j.ijrobp.2019.02.054
De-Escalation Strategies in HPV-Associated Oropharynx Cancer-Are we Putting the Cart Before the Horse?
Comment in
-
Cetuximab and Radiation Therapy in Head and Neck Cancer.Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):678-679. doi: 10.1016/j.ijrobp.2019.07.025. Int J Radiat Oncol Biol Phys. 2019. PMID: 31540600 No abstract available.
Comment on
-
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.Lancet. 2019 Jan 5;393(10166):51-60. doi: 10.1016/S0140-6736(18)32752-1. Epub 2018 Nov 15. Lancet. 2019. PMID: 30449623 Free PMC article. Clinical Trial.
-
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.Lancet. 2019 Jan 5;393(10166):40-50. doi: 10.1016/S0140-6736(18)32779-X. Epub 2018 Nov 15. Lancet. 2019. PMID: 30449625 Free PMC article. Clinical Trial.
Similar articles
-
HPV-associated oropharyngeal cancer de-escalation strategies and trials: Past failures and future promise.J Surg Oncol. 2021 Nov;124(6):962-966. doi: 10.1002/jso.26696. Epub 2021 Sep 30. J Surg Oncol. 2021. PMID: 34595766 Free PMC article. Review.
-
Cetuximab in Human Papillomavirus-Positive Oropharynx Carcinoma.J Clin Oncol. 2016 Apr 20;34(12):1289-91. doi: 10.1200/JCO.2015.65.1414. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884569 No abstract available.
-
Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?Am Soc Clin Oncol Educ Book. 2019 Jan;39:364-372. doi: 10.1200/EDBK_238315. Epub 2019 May 17. Am Soc Clin Oncol Educ Book. 2019. PMID: 31099643 Review.
-
Radiation Dose De-Escalation in HPV-Positive Oropharynx Cancer: When Will It Be an Acceptable Standard of Care?J Clin Oncol. 2021 Mar 20;39(9):947-949. doi: 10.1200/JCO.21.00017. Epub 2021 Feb 12. J Clin Oncol. 2021. PMID: 33577355 No abstract available.
-
Human papillomavirus-related oropharyngeal cancer.Ann Oncol. 2017 Oct 1;28(10):2386-2398. doi: 10.1093/annonc/mdx304. Ann Oncol. 2017. PMID: 28633362 Review.
Cited by
-
Novel Strategies for Managing Retropharyngeal Lymph Node Metastases in Head and Neck and Thyroid Cancer with Transoral Robotic Surgery (TORS).Ann Surg Oncol. 2022 Nov;29(12):7881-7890. doi: 10.1245/s10434-022-12208-6. Epub 2022 Jul 16. Ann Surg Oncol. 2022. PMID: 35842533 Review.
-
p53 Modulates Radiosensitivity in Head and Neck Cancers-From Classic to Future Horizons.Diagnostics (Basel). 2022 Dec 5;12(12):3052. doi: 10.3390/diagnostics12123052. Diagnostics (Basel). 2022. PMID: 36553058 Free PMC article. Review.
-
GA-OH enhances the cytotoxicity of photon and proton radiation in HPV+ HNSCC cells.Front Oncol. 2023 Feb 10;13:1070485. doi: 10.3389/fonc.2023.1070485. eCollection 2023. Front Oncol. 2023. PMID: 36845698 Free PMC article.
-
Survival Outcomes and Treatment Decision by Human Papillomavirus Status Among Patients With Stage IVC Head and Neck Squamous Cell Carcinoma.Front Oncol. 2021 May 31;11:668066. doi: 10.3389/fonc.2021.668066. eCollection 2021. Front Oncol. 2021. PMID: 34136400 Free PMC article.
-
Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirations.J Pathol Clin Res. 2022 Jan;8(1):3-13. doi: 10.1002/cjp2.246. Epub 2021 Oct 17. J Pathol Clin Res. 2022. PMID: 34658150 Free PMC article. Review.
References
-
- Marur S, Li S, Cmelak AJ, et al. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol 2017; 35(5): 490–7. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources